FDMT - Goldman reinstates buy rating on 4D Molecular cites upcoming catalysts
2024-02-08 18:40:34 ET
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
- 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
- 4D Molecular Therapeutics up 3%, prices $300M equity
- Biggest stock movers today: Nvidia, Air Products and Chemicals, Estee Lauder, 4D Molecular Therapeutics, and more
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics